MD Magazine (3/5, Walter) reports, “The response rate of antidepressant medications can be low when pharmacogenomics are not taking into account for patients suffering from major depressive disorder (MDD),” researchers concluded after examining “the success of guided-care compared to common treatment for major depressive disorder in a 24-week, randomized, controlled” study called “The Genomics Used to Improve DEpression Decisions (GUIDED) trial.” The study “included 1167 outpatient diagnosed with” MDD. The findings were published last April in the Journal of Psychiatric Research.

Related Links:

— “Pharmacogenomics Effective for Major Depressive Disorder Patients, “Kenny Walter, MD Magazine, March 5, 2020

The Washington Post (3/4, Dreier) reports that on March 4, “seeking to end a practice that one senator called a ‘profound betrayal of trust,’ legislation was…in the Senate and House of Representatives to stop the Trump administration from using confidential therapy notes against immigrant children in detention and deportation proceedings.” This “legislation is one of several efforts underway to protect the confidentiality of young asylum-seekers launched after The Washington Post reported that Immigration and Customs Enforcement (ICE) has been regularly using notes from therapy sessions against unaccompanied minors, often without the consent of the therapists involved, and always without the consent of the minors themselves.”

Related Links:

— “Bill would end practice of using confidential therapy notes against detained immigrant children, “Hannah Dreier, The Washington Post, March 4, 2020

The AP (3/4, Perrone) reports that on March 4, the FDA “banned electrical shock devices used to discourage aggressive, self-harming behavior in patients with mental disabilities.” The agency’s announcement “follows years of pressure from patient groups and mental health experts who have called the treatment outdated, ineffective and unethical.”

Reuters (3/4, Joseph) reports that in its “final decision,” the FDA cited “substantial risks of illness or injury to patients.” The FDA’s “decision comes after the devices were found to cause tissue damage and worsen underlying symptoms, leading to depression, anxiety and post-traumatic stress disorder.”

According to MedPage Today (3/4, Gever), just one clinic in the US “is believed to use this form of ‘aversive therapy,’ the Judge Rotenberg Educational Center (JRC) in Canton, Massachusetts, where the FDA said it believes some 45 to 50 people ‘are currently being exposed’ to the treatment.” The FDA’s ban, however, “does not apply to electrical stimulation devices used for other ‘aversive’ therapies, such as those approved for smoking cessation,” nor are “non-aversive electrical stimulators, such as for cranial electrotherapy,” affected by the ban.

Related Links:

— “FDA bans shock device used on mentally disabled patients, “Matthew Perrone, AP, March 4, 2020

Healio (3/4, Gramigna) reports, “Suicide risk is higher at night than any other time of day,” investigators concluded in a study that “found no significant variation in this risk by method, month or demographic characteristics.” For the study, the study team “collected time, date, method and demographic information for 35,338 suicides included in the National Violent Death Reporting System between 2003 and 2010,” then “compared the estimated hourly proportion of the population awake from the American Time Use Survey for 2003 to 2010 with the time of fatal injury, which was grouped into one-hour bins.” The study revealed that “across all months and methods, risk for suicide was higher at night.” The findings were published online Feb. 25 in the Journal of Clinical Psychiatry.

Related Links:

— “Suicide risk significantly elevated at night, “Joe Gramigna, Healio, March 4, 2020

Psychiatric News (3/4) reports, “The risk of suicide among physicians who are women appears to be higher than women in the general population,” investigators concluded. Investigators “found that women physicians were 46% more likely than women in the general population to die by suicide.” In contrast, “men physicians were 33% less likely than men in the general population to die by suicide.” The findings of the nine-study meta-analysis and systematic review were published online March 4 in JAMA Psychiatry.

Related Links:

— “Meta-Analysis Spotlights Challenge of Physician Suicide, Psychiatric News, March 4, 2020